Moduladores y potenciadores para el tratamiento de personas con fibrosis quística con mutaciones Clase II (F508del) en el CFTR

Comisión Nacional de Evaluación de Tecnologías de Salud (CONETEC) (CONETEC).
s.l; CONETEC; ago. 2022.
Não convencional Espanhol | BRISA | ID: biblio-1391934

Documentos relacionados

  1. Digital technologies and implications for Veterinary Services.
  2. Elexacaftor-Tezacaftor-Ivacaftor en fibrosis quística
  3. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.
  4. A global community-sourced assessment of the state of conservation technology.
  5. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.
  6. Fibrosis quística: patogenia bacteriana y moduladores del CFTR (regulador de conductancia transmembranal de la fibrosis quística).
  7. Measuring the impacts of aquatic animal diseases: the role of economic analysis.
  8. Tax-funded social health insurance: an analysis of revenue sources, Hungary.
  9. Cystic fibrosis outpatient treatment and medical costs: a retrospective analysis
  10. Assessment of the Risk and Economic Burden of Surgical Site Infection Following Colorectal Surgery Using a US Longitudinal Database: Is There a Role for Innovative Antimicrobial Wound Closure Technology to Reduce the Risk of Infection?